相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma
Casey J. N. Mathison et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma
Modi Wang et al.
BIOORGANIC CHEMISTRY (2019)
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
Alexander Drilon et al.
CANCER DISCOVERY (2019)
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Alexander Drilon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Selective RET kinase inhibition for patients with RET-altered cancers
V. Subbiah et al.
ANNALS OF ONCOLOGY (2018)
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors
Valeria La Pietra et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants
Jiao Yang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS
Hilary Schenck Eidam et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived
Wade T. Iams et al.
CANCER DISCOVERY (2018)
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
Vivek Subbiah et al.
CANCER DISCOVERY (2018)
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion
Zofia Piotrowska et al.
CANCER DISCOVERY (2018)
Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations
Gang G. Li et al.
CLINICAL CANCER RESEARCH (2017)
Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor
Hojong Yoon et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Aminoisoquinoline benzamides, FLT3 and Src-family kinase inhibitors potently inhibit proliferation of acute myeloid leukemia cell lines
Elizabeth Larocque et al.
FUTURE MEDICINAL CHEMISTRY (2017)
Cabozantinib in the treatment of hepatocellular carcinoma
Mary Linton B. Peters et al.
FUTURE ONCOLOGY (2017)
Discovery of wtRET and V804MRET Inhibitors: From Hit to Lead
Luca Mologni et al.
CHEMMEDCHEM (2017)
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer
Valentina De Falco et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon-specific penetrance and changes in management during the last four decades
L. Mucha et al.
CLINICAL ENDOCRINOLOGY (2017)
Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors
Chengyan Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants
Hojong Yoon et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position
Allan M. Jordan et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Discovery of 4-chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl) benzamides as novel RET kinase inhibitors
Mei Han et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity
Rebecca Newton et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients
Sha Fu et al.
PLOS ONE (2015)
Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N′-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily
Valentina Gandin et al.
SCIENTIFIC REPORTS (2015)
Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
Cristina Romei et al.
CLINICAL ENDOCRINOLOGY (2015)
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: Design, synthesis and evaluation
Brendan Frett et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies
Stefania Sartini et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non-Small Cell Lung Cancer
Tatsushi Kodama et al.
MOLECULAR CANCER THERAPEUTICS (2014)
RET revisited: expanding the oncogenic portfolio
Lois M. Mulligan
NATURE REVIEWS CANCER (2014)
Structural studies of GDNF family ligands with their receptors-Insights into ligand recognition and activation of receptor tyrosine kinase RET
Xinquan Wang
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2013)
Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
Kiyoshi Okamoto et al.
CANCER LETTERS (2013)
RET inhibition: implications in cancer therapy
Maria Grazia Borrello et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
Ponatinib (AP24534) Is a Novel Potent Inhibitor of Oncogenic RET Mutants Associated With Thyroid Cancer
Valentina De Falco et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase
Luca Mologni et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
Young Seok Ju et al.
GENOME RESEARCH (2012)
Preparation of 3-Substituted-1-Isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET Kinase Inhibitors
Peter Diner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E
Martin W. Rowbottom et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology
Arvin C. Dar et al.
NATURE (2012)
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells
Guido Bocci et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Vandetanib First Global Approval
Helen Commander et al.
DRUGS (2011)
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors
Luca Mologni et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl) nicotinonitrile scaffold
Wiebke Brandt et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2010)
Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC
Karin Frank-Raue et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2010)
Structure and chemical inhibition of the RET tyrosine kinase domain
Phillip P. Knowles et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors
Jan Willem B. de Groot et al.
ENDOCRINE REVIEWS (2006)
Conservation of RET proto-oncogene splicing variants and implications for RET isoform function
MT Carter et al.
CYTOGENETICS AND CELL GENETICS (2001)
分享论文
